Evidence map›Paper›PMID 39940694›Full record

ArticleInternational journal of molecular sciences2025

The High Levels of Soluble Receptors for Tumor Necrosis Factor and Heart Injury in Children with the Pediatric Inflammatory Multisystem Syndrome Associated with Coronavirus Infection: Is This Just a Coincidence? A Proof-of-Concept Study.

Maciej Marczak, Alicja Krejner-Bienias, Agnieszka Jasińska, Marek Kulus, Paweł Miklis, Katarzyna Grzela, Tomasz Grzela

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Maciej MarczakDepartment of Pediatric Pulmonology and Allergy, Medical University of Warsaw, 02-091 Warsaw, Poland.
Alicja Krejner-BieniasDepartment of Pediatric Pulmonology and Allergy, Medical University of Warsaw, 02-091 Warsaw, Poland.
Agnieszka JasińskaDepartment of Pediatric Pulmonology and Allergy, Medical University of Warsaw, 02-091 Warsaw, Poland.
Marek KulusDepartment of Pediatric Pulmonology and Allergy, Medical University of Warsaw, 02-091 Warsaw, Poland.
Paweł MiklisDepartment of Pediatric Pulmonology and Allergy, Medical University of Warsaw, 02-091 Warsaw, Poland.
Katarzyna GrzelaDepartment of Pediatric Pulmonology and Allergy, Medical University of Warsaw, 02-091 Warsaw, Poland.ORCID 0000-0003-2876-104X
Tomasz GrzelaDepartment of Histology and Embryology, Medical University of Warsaw, 02-004 Warsaw, Poland.ORCID 0000-0001-8519-4868

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

(1) Pediatric inflammatory multisystem syndrome (PIMS) is a relatively rare complication of coronavirus disease (COVID-19). So far, it is unclear why COVID-19 in children has usually mild or asymptomatic courses, whereas PIMS, which develops several weeks after COVID-19, is a serious life-threatening condition. (2) In this proof-of-concept study, using the ELISA method, we compared selected clinical and immunological parameters in small groups of children with PIMS and COVID-19. Children with various inflammatory diseases were included as a control. (3) Patients with PIMS revealed significantly higher levels of pro-inflammatory molecules (C-reactive protein and IL-6) and markers of heart injury (troponin I and N-terminal prohormone of brain natriuretic peptide) as compared to other groups. Moreover, these markers correlated with increased levels of soluble receptors for tumor necrosis factor (sTNF-R1 and sTNF-R2). (4) Our observation may be a step forward to better understand the phenomenon of mild COVID-19 in children and its severe complications in PIMS. It is hypothesized that the delayed inflammation results in excessive cardiomyocyte damage and the release of sTNF-R1 and -R2. Therefore, possibly the involvement of the TNF pathway in PIMS could be explored as a potential therapeutic target. However, further studies are required to validate this approach.

Indexed as

COVID-19Heart InjuriesReceptors, Tumor Necrosis Factor, Type IReceptors, Tumor Necrosis Factor, Type IISystemic Inflammatory Response SyndromeAdolescentBiomarkersChildChild, PreschoolC-Reactive ProteinFemaleHumansInterleukin-6MaleNatriuretic Peptide, BrainPeptide FragmentsBiomarkersC-Reactive ProteinInterleukin-6Natriuretic Peptide, BrainPeptide FragmentsReceptors, Tumor Necrosis Factor, Type IReceptors, Tumor Necrosis Factor, Type IITNFRSF1A protein, humanTroponin Icoronavirus diseaseCOVID-19heart injuryNT-proBNPpediatric inflammatory multisystem syndromePIMSTNFTNF-Rtumor necrosis factortumor necrosis factor-receptor

Identifiers

PMID39940694
PMCPMC11817279

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.